Protagonist Therapeutics, Inc.

Protagonist Therapeutics Beats on EPS, Stock Down 0.1%

Protagonist Therapeutics reported a better-than-expected EPS, which indicates some positive momentum in their financials. However, the stock reacted slightly down by 0.1%, likely due to the lack of revenue information and no guidance for future performance. Investors may be cautious as they await more detailed updates on the company's pipeline and financial outlook.